4 completed, 3 recruiting, 2 active not recruiting, 1 withdrawn. 4 Phase 2, 2 Not applicable, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Completed 1, Recruiting 1 |
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Clear Cell Carcinoma: new trials by email Literature Review of Clear Cell Carcinoma trials Research Report on Clear Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma Lymphodepleting chemotherapy, Dexamethasone, Fludarabine - Clear Cell Carcinoma, Phase 1 | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 30 | 2025-09-25 | 2026-04-29 |
| A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy 3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | North Eastern German Society of Gynaecological Oncology | 640 | 2024-10-11 | 2026-10-23 |
| A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) Dostarlimab, Bevacizumab, Doxorubicin - Ovarian Neoplasms, Endometrial Neoplasms | Phase 2 | Active not recruiting | Yonsei University | 198 | 2024-01-22 | 2026-11-02 |
| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies vudalimab - Ovarian Cancer, Clear Cell Carcinoma | Phase 2 | Active not recruiting | Xencor, Inc. | 170 | 2022-07-21 | 2025-02-07 |
| Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus. Image-guided adjuvant pelvic radiotherapy - Endometrioid Adenocarcinoma, Serous Carcinoma | Not applicable | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 23 | 2020-08-26 | 2025-08-01 |
| Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients Rucaparib, Placebos - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Completed | North Eastern German Society of Gynaecological Oncology | 42 | 2020-06-08 | 2024-11-15 |
| An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy 13C-Glucose, 13C-Acetate, 13C-Lactate - Kidney Cancer, Renal Cell Carcinoma | Not applicable | Recruiting | University of Texas Southwestern Medical Center | 600 | 2019-09-30 | 2026-01-28 |
| A Study of Nivolumab in Selected Uterine Cancer Patients Nivolumab - Uterine Cancer, Endometrial Carcinoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 35 | 2017-08-03 | 2024-12-27 |
| Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC) Endometrioid Carcinoma, Clear Cell Carcinoma | Withdrawn | University Hospital, Basel, Switzerland | 2012-10-01 | 2015-04-01 | ||
| A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas alemtuzumab, fludarabine, sirolimus - Ewing Sarcoma, Gastrointestinal Tumor | Phase 1 | Completed | St. Jude Children's Research Hospital | 23 | 2012-08-20 | 2026-02-06 |
Adenocarcinoma, Clear Cell (10) · Ovarian Neoplasms (4) · Endometrial Neoplasms (3) · Fallopian Tube Neoplasms (3) · Carcinoma, Endometrioid (2) · Carcinoma, Renal Cell (2) · Carcinosarcoma (2) · Uterine Cervical Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Transitional Cell (1) · Cystadenocarcinoma, Serous (1) · Digestive System Neoplasms (1) · Endometriosis (1) · Fumaric aciduria (1) · Hereditary leiomyomatosis and renal cell cancer (1)
Adenocarcinoma (10) · Carcinoma (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms, Glandular and Epithelial (10) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Neoplasms by Site (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Genital Diseases (7) · Genital Diseases, Female (7) · Genital Neoplasms, Female (7) · Adnexal Diseases (6) · Endocrine System Diseases (6)
fludarabine (2) · Alemtuzumab (1) · Bevacizumab (1) · Busulfan (1) · Dexamethasone (1) · Doxorubicin (1) · Gemcitabine (1) · Melphalan (1) · Nivolumab (1) · Paclitaxel (1) · Sirolimus (1) · Stem Cell Transplantation (1) · dostarlimab (1) · liposomal doxorubicin (1) · rucaparib (1)
North Eastern German Society of Gynaecological Oncology (2) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · St. Jude Children's Research Hospital (1) · University Hospital, Basel, Switzerland (1) · University of Texas Southwestern Medical Center (1) · Xencor, Inc. (1) · Yonsei University (1)
United States (5) · Germany (2) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Czechia (1) · Hong Kong (1) · Italy (1) · Japan (1) · Singapore (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Andrew C Johns, MD (1) · Brando Triplett, MD (1) · Claire Friedman, MD (1) · David D'Souza, M.D. (1) · Ellen C Obermann, MD (1) · Ellen Obermann, MD, Dr. (1) · Jalid Sehouli, Prof. Dr. (1) · Jalid Sehouli, Prof. Dr. med. (1) · Jolene Shorr (1) · Vitaly Margulis, MD (1)
PMID 38653864, PMID 39710508, PMID 39990653, PMID 40382284, PMID 42140839
F31CA239330 (1), P50CA196516 (1), R35CA220449 (1)